Roth Capital Lowers Earnings Estimates for Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Investment analysts at Roth Capital cut their Q1 2026 earnings estimates for Niagen Bioscience in a research report issued on Wednesday, October 1st. Roth Capital analyst S. Mcgowan now expects that the company will earn $0.03 per share for the quarter, down from their prior forecast of $0.04. Roth Capital currently has a “Buy” rating and a $23.00 target price on the stock.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

NAGE has been the topic of several other reports. Wall Street Zen cut Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. HC Wainwright raised their price target on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, August 11th. Finally, Canaccord Genuity Group lifted their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $13.42.

Niagen Bioscience Trading Down 6.5%

Niagen Bioscience stock opened at $7.38 on Thursday. Niagen Bioscience has a 12 month low of $3.18 and a 12 month high of $14.69. The stock has a fifty day simple moving average of $9.62 and a two-hundred day simple moving average of $9.47. The firm has a market cap of $588.56 million, a price-to-earnings ratio of 35.14 and a beta of 2.13.

Institutional Trading of Niagen Bioscience

Large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC bought a new position in Niagen Bioscience in the fourth quarter worth approximately $74,000. Deutsche Bank AG increased its stake in shares of Niagen Bioscience by 1,733.4% in the 4th quarter. Deutsche Bank AG now owns 26,878 shares of the company’s stock worth $143,000 after purchasing an additional 25,412 shares in the last quarter. Bank of America Corp DE raised its holdings in Niagen Bioscience by 89.5% in the 4th quarter. Bank of America Corp DE now owns 52,144 shares of the company’s stock worth $277,000 after purchasing an additional 24,622 shares during the period. Squarepoint Ops LLC purchased a new position in Niagen Bioscience during the fourth quarter valued at $555,000. Finally, Two Sigma Investments LP purchased a new position in Niagen Bioscience during the fourth quarter valued at $675,000. 15.41% of the stock is currently owned by institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.